| Previous Close | 83.27 |
| Open | 83.41 |
| Bid | 83.08 x 200 |
| Ask | 83.09 x 400 |
| Day's Range | 83.01 - 84.28 |
| 52 Week Range | 63.76 - 86.27 |
| Volume | 5,499,749 |
| Avg. Volume | 9,365,871 |
| Market Cap | 108.43B |
| Beta | 0.91 |
| PE Ratio (TTM) | 9.02 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.53%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
- Barrons.com•4 hours ago
Now That Gilead's Bought Kite, Are Doctors Ready To Use CAR T Cancer Therapy?
In the fight against cancer, CAR T therapies are growing in popularity. Butler and Cha surveyed 25 hematologists/oncologists about their thoughts on potentially using CAR T therapy in appropriate patients within their practices, beginning before the Gilead-Kite Pharma deal was announced, and the results appear to be good news. From the note: Our findings suggest that the majority of surveyed hematologists/oncologists are familiar with CAR T therapy, and plan to use the therapy for either r/r ALL [relapsed and refractory acute lymphoblastic leukemia] or r/r DLBCL [diffuse large B-cell lymphoma] patients.
- Motley Fool•3 days ago
Oddly, Juno Therapeutics Is Jumping 11.3% Today
Optimism that it can develop CAR-T cancer drugs that are better than its competitors' is trumping news that the company is diluting investors by selling more shares.
- Zacks•3 days ago
Gilead's (GILD) Epclusa Receives Label Expansion in Canada
Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.
